secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2026-02-10T23:59:59+00:00
Accession:  0001099800-26-000006
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q4 sales $1.57B (+13.3%), TAVR +12%, TMTT >40% growth; FY2026 guidance raised
--------------------------------------------------------------------------------

- Q4 GAAP EPS $0.11, adjusted EPS $0.58; gross margin 78.1% (78.3% adjusted).
- TAVR sales $1.16B (+12.0%); TMTT sales $156M (+40%). Full-year sales growth 11.5%.
- FY2026 outlook: constant-currency sales growth 8–10%, adjusted EPS $2.90–$3.05.
- FDA approved SAPIEN M3, first transcatheter mitral replacement; CMS opened TAVR NCD reconsideration.
- Q1 2026 guidance: sales $1.55–$1.63B, adjusted EPS $0.70–$0.76.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980026000006/0001099800-26-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980026000006/ew-20260210.htm
  HTML page:      https://secwatch.observer/filing/0001099800-26-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer